Andrew Partheniou
Recent Articles
Biotech at Good Entry Point for Investors, Analyst Says 12/20/2022
The company, focused on psychedelic-assisted psychotherapies to better treat addiction, is worth more than the CA$10 million the market is valuing it at, noted a Stifel report.
Co. Pursuing Ketamine for Addiction Forms Partnership 08/16/2022
In landing this first licensing deal, the life sciences firm "shows good progress towards a potentially high-margin business," noted a Stifel report.
Analyst Sees 'Attractive Long-Term Economics' for Healthcare Co. 07/13/2022
One healthcare company with upcoming catalysts wants to take a share of the CA$6-billion alcoholism treatment market with its proprietary psychedelic-assisted psychotherapy treatments.
Recent Quotes
"AWKN announced its first KARE licensing agreement."
—
Andrew Partheniou, Stifel
(8/15/22)
more >
"AWKNF shares offer an attractive risk-reward profile."
—
Andrew Partheniou, Stifel
(3/31/22)
more >
